Expert Opinion on Investigational Drugs, Volume 30, Issue 2 (2021)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Investigational Drugs, Volume 30, Issue 2 (2021)

See all volumes and issues
Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Volume 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994
Download citations Download PDFs Download issue

Editorial

Editorial
Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development
Ernest A. Adeghate, Huba Kalász, Saeeda Al Jaberi, Jennifer Adeghate & Kornelia Tekes
Pages: 85-93
Published online: 28 Dec 2020
First Page PreviewforTackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development | Full Text | References | PDF (289.5 KB) | EPUB
  • 2463 Views
  • 9 CrossRef citations
  • 0Altmetric
Free Access

Drug Evaluation

Article
Adrecizumab: an investigational agent for the biomarker-guided treatment of sepsis
Benjamin Deniau, Koji Takagi, Ayu Asakage & Alexandre Mebazaa
Pages: 95-102
Published online: 21 Dec 2020
AbstractforAdrecizumab: an investigational agent for the biomarker-guided treatment of sepsis | Full Text | References | PDF (743.9 KB) | EPUB
  • 678 Views
  • 6 CrossRef citations
  • 0Altmetric
Article
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer
Antonella Pietragalla, Simona Duranti, Gennaro Daniele, Camilla Nero, Francesca Ciccarone, Domenica Lorusso, Anna Fagotti & Giovanni Scambia
Pages: 103-110
Published online: 11 Jan 2021
AbstractforOregovomab: an investigational agent for the treatment of advanced ovarian cancer | Full Text | References | PDF (348.2 KB) | EPUB
  • 505 Views
  • 6 CrossRef citations
  • 0Altmetric

Perspective

The design and analysis of non-randomized studies: a case study of off-label use of hydroxychloroquine in the COVID-19 pandemic
Derek Shyr & Yu Shyr
Pages: 111-117
Published online: 29 Dec 2020
AbstractforThe design and analysis of non-randomized studies: a case study of off-label use of hydroxychloroquine in the COVID-19 pandemic | Full Text | References | PDF (1.1 MB) | EPUB
  • 2316 Views
  • 0 CrossRef citations
  • 0Altmetric

Review

The time to develop treatments for diabetic neuropathy
Marc S. Rendell
Pages: 119-130
Published online: 11 Jan 2021
AbstractforThe time to develop treatments for diabetic neuropathy | Full Text | References | PDF (344.8 KB) | EPUB
  • 332 Views
  • 4 CrossRef citations
  • 0Altmetric
Investigational drugs in early phase development for primary biliary cholangitis
Eric M. Gochanour & Kris V. Kowdley
Pages: 131-141
Published online: 11 Dec 2020
AbstractforInvestigational drugs in early phase development for primary biliary cholangitis | Full Text | References | PDF (878.5 KB) | EPUB
  • 386 Views
  • 5 CrossRef citations
  • 0Altmetric
Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib
Mahmoud Mohammadi & Hans Gelderblom
Pages: 143-152
Published online: 03 Dec 2020
AbstractforSystemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib | Full Text | References | PDF (1.2 MB) | EPUB
  • 4707 Views
  • 11 CrossRef citations
  • 0Altmetric
Open Access
Cardiac fibrosis: emerging agents in preclinical and clinical development
Roberto Spoladore, Giulio Falasconi, Giorgio Fiore, Silvana Di Maio, Alberto Preda, Massimo Slavich, Alberto Margonato & Gabriele Fragasso
Pages: 153-166
Published online: 04 Jan 2021
AbstractforCardiac fibrosis: emerging agents in preclinical and clinical development | Full Text | References | PDF (1.6 MB) | EPUB
  • 539 Views
  • 5 CrossRef citations
  • 0Altmetric
Article
Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies
Omar Sheikh & Toshifumi Yokota
Pages: 167-176
Published online: 06 Jan 2021
AbstractforDeveloping DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies | Full Text | References | PDF (344 KB) | EPUB
  • 2167 Views
  • 32 CrossRef citations
  • 0Altmetric

Original research

Article
Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma
Min-Jung Lee, Yusuke Tomita, Akira Yuno, Sunmin Lee, Nacer E. Abrouk, Bryan Oronsky, Scott Caroen & Jane B. Trepel
Pages: 177-183
Published online: 11 Jan 2021
AbstractforResults from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma | Full Text | References | PDF (1.9 MB) | EPUB
  • 250 Views
  • 5 CrossRef citations
  • 0Altmetric

Original Research

Article
Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects
Hong Zhang, Cuiyun Li, Jingrui Liu, Min Wu, Xiaojiao Li, Xiaoxue Zhu, Qianqian Li, Boguang Wang, Yanhong Mao, Yanhua Ding & Qinglong Jin
Pages: 185-192
Published online: 22 Dec 2020
AbstractforSafety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects | Full Text | References | PDF (2.8 MB) | EPUB | Supplemental
  • 331 Views
  • 7 CrossRef citations
  • 0Altmetric

Explore articles